
Sign up to save your podcasts
Or
Antibody-drug conjugates (ADCs) are new chemotherapeutic agents that can cause significant ocular side effects. Drs. Meghan Berkenstock, Lauren Dalvin, and Stella Kim review this new class of drugs and how they can affect the eye, providing essential tips for what to look for, when to screen, and how to treat the side effects. Prescribing information mentioned in this episode: Elahere (mirvetuximab soravtansine-gynx) Tivdak (tisotumab vedotin-tftv)
For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts.
4.9
5050 ratings
Antibody-drug conjugates (ADCs) are new chemotherapeutic agents that can cause significant ocular side effects. Drs. Meghan Berkenstock, Lauren Dalvin, and Stella Kim review this new class of drugs and how they can affect the eye, providing essential tips for what to look for, when to screen, and how to treat the side effects. Prescribing information mentioned in this episode: Elahere (mirvetuximab soravtansine-gynx) Tivdak (tisotumab vedotin-tftv)
For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts.
43 Listeners
17 Listeners
5 Listeners
276 Listeners
8 Listeners
10 Listeners
20 Listeners
10 Listeners
10 Listeners
1 Listeners
18 Listeners
16 Listeners
16 Listeners
3 Listeners
0 Listeners